Erratum: Rationale, study design and implementation of the COLM study: The combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients (Hypertension Research (2009) 32 (163-167) DOI: 10.1038/hr.2008.31);Rationale, study design and implementation of the COLM study: The combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients

Hypertension Research

Volumn 32, Issue 2, 2009, Pages 163-167

  Ogihara, Toshio ^a   Saruta, Takao ^b   Rakugi, Hiromi ^a   Shimamoto, Kazuaki ^c   Ito, Sadayoshi ^d   Matsuoka, Hiroaki ^e   Horiuchi, Masatsugu ^f   Imaizumi, Tsutomu ^g   Takishita, Shuichi ^h   Higaki, Jitsuo ^f   Katayama, Shigehiro ⁱ   Saito, Ikuo ^b   Shimada, Kazuyuki ^j  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e DOKKYO MEDICAL UNIVERSITY   (Japan)

^f EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h UNIVERSITY OF THE RYUKYUS   (Japan)

ⁱ SAITAMA MEDICAL UNIVERSITY   (Japan)

^j JICHI MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; AZELNIDIPINE; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; INDAPAMIDE; MEFRUSIDE; METICRANE; OLMESARTAN; THIAZIDE DIURETIC AGENT; TRICHLORMETHIAZIDE; TRIPAMIDE; UNCLASSIFIED DRUG;

AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; JAPAN; LOW DRUG DOSE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DIURETICS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; JAPAN; MALE; PROSPECTIVE STUDIES; RISK; TETRAZOLES;

EID: 68249147700     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.35     Document Type: Erratum

References (24)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality; a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
3. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: A meta-analysis. Lancet 2001; 358: 1305-1315.
4. Japanese Society of Hypertension. Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 2006; 29: S1-S105.
5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ, Joint National Committee on Prevention, Detection, Evaluation, Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
6. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchefti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtern U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B, Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology\par. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension(ESH) and of the European Society of Cardiology(ESC). J Hypertens 2007; 25: 1105-1187.
7. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: The cycle repeats. Drugs 2002; 62: 443-462.
8. Kamijima Y, Ooba N, Yagame M, Samizo K, Shimodozono Y, Kageyama S, Horiguchi S, Nagai R, Kusunoki T, Kubota K. Hypertension management in diabetic patients: Prescribing trends from 1999 to 2005 in three Japanese university hospitals. Pharmacoepidemiol Drug Saf 2008; 17: 904-911.
9. Brunner HR, Arakawa K. Antihypertensivé efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-h blood pressure reductions and ambulatory blood pressure goals. Clin Drug Investig 2006; 26: 185-193.
10. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of almesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283-291, 318.
11. Saito I, Kushiro T, Hirata K, Sato Y, Kobayashi F, Sagawa K, Hiramatsu K, Komiya M. The use of olmesartan medoxomil as monotherapy or in combination with other antihypertensive agents in elderly hypertensive patients in Japan. J Clin Hypertens 2008; 10: 272-279.
12. Nakayama S, Watada H, Mita T, Ikeda F, Shimizu T, Uchino H, Fujitani Y, Hirose T, Kawamori R. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res 2008; 31: 7-13.
13. Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press 1992; 1: 113-119.
14. Ogihara T. Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan. Am J Hypertens 2000; 13: 461-467.
15. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-663.
16. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-556.
17. Stergiou GS, Makris T, Papavasiliou M, Efstathiou S, Manolis A. Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J Hypertens 2005; 23: 883-889.
18. Neutel JM, Smith DH, Silfani TN, Lee Y, Weber MA. Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. J Hum Hypertens 2006; 20: 255-262.
19. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beavers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT Investigators. Prevention of cardiovascular events with an anti hypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure' Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005; 366:895-906.
20. Jamerson KA, Bakris GL, Wun CC, Dahlöf B, Lefkowitz M, Manfreda S, Pitt B, Velazquez EJ, Weber MA. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: The first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens 2004; 17 793-801.
21. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, for the Accomplish trial investigators. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. N Engl J Med 2008; 359: 2417-2428.
22. Matcher DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP, Gray RN. Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension. Ann Intern Med 2008; 148: 16-29.
23. Murai K, Obara T, Ohkubo T, Metoki H, Oikawa T, Inoue R, Komai R, Horikawa T, Asayama K, Kikuya M, Totsune K, Hashimoto J, Imai Y, J-Home Study Group. Current usage of diuretics among hypertensive patients in Japan: The Japan Home Versus Office blood Pressure Measurement Evaluation (J-HOME) Study. Hypertens Res 2006; 29: 857-863.
24. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: Greater precision but with greater uncertainty? JAMA 2003; 289: 2554-2559.